In arthritis and hypersensitivity models, we found that DC and DC-derived exosomes modified to express either soluble or membrane-bound IL-4 were equally capable of ameliorating disease, indicating that the delivery of high levels of IL-4 alone were not the sole driving factor in the therapeutic effect [20]. This evidence concerns the gene IL4 and arthritic joint disease.